TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15231001

Group type: EXPERIMENTAL
Intervention: Behavioural counselling
Number of subjects: 271

Group type: COMPARATOR
Intervention: Nutritional education counselling
Number of subjects: 271
Study: 11128341

Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg once a day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nisoldipine (20-40 mg once a day)
Number of subjects: 48
Study: 9371877

Group type: EXPERIMENTAL
Intervention: [123I]FE-CIT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: [123I]FP-CIT
Number of subjects: 6
Study: 8104107

Group type: EXPERIMENTAL
Intervention: Low SFA‐‐cholesterol (LSC) diet for 5 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High SFA‐‐cholesterol (HSC) diet for 5 weeks
Number of subjects: 37
Study: 3522031

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 30345611

Group type: EXPERIMENTAL
Intervention: 1 dose of ranibizumab + pro re nata (prn)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3 doses of ranibizumab + pro re nata (prn)
Number of subjects: 50
Study: 28691269

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/hour infusion)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Normal saline (same bolus and infusion rate as lidocaine)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 148
Study: 27317550

Group type: EXPERIMENTAL
Intervention: Ametop™ (tetracaine 4%) gel applied to the skin of the lower back at least 20min before neuraxial block
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo applied to the skin of the lower back at least 20min before neuraxial block
Number of subjects: 72
Study: 25157013

Group type: EXPERIMENTAL
Intervention: Multifaceted controlled intervention
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall composite measure
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 21971356

Group type: EXPERIMENTAL
Intervention: High-titer neutralizing antibodies (NAb) against two or more isolates (90% inhibitory dose > 500)
Number of subjects: 50
Study: 19857447

Group type: EXPERIMENTAL
Intervention: 3 μg IXIARO®
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 μg IXIARO®
Number of subjects: 60

Group type: COMPARATOR
Intervention: JenceVac™
Number of subjects: 60
Study: 17977528

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prolonged abstinence
Number of subjects: 31
Study: 15095213

Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg per week for 8 weeks (R1)
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Azithromycin, 1500 mg once at enrollment (R2)
Number of subjects: 1683

Group type: COMPARATOR
Intervention: No therapy (R3)
Number of subjects: 1683
Study: 11806304

Group type: EXPERIMENTAL
Intervention: H1 antihistamines
Number of subjects: 0
Study: 9551842

Group type: EXPERIMENTAL
Intervention: Tiagabine (10 mg three-times daily)
Number of subjects: 154
Study: 7998046

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 3051945

Group type: EXPERIMENTAL
Intervention: CG-120 (3 or 4 g daily)
Number of subjects: 398
Study: 1100041

Group type: EXPERIMENTAL
Intervention: Plimasin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pyrobenzamine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31588557

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Radiotherapy after breast conservation
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Oncotype DX
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Contralateral prophylactic mastectomy
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Ordering of Oncotype DX
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Use of endocrine therapy
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Older age, black race, higher Charlson Comorbidity Index, high tumor grade and stage of disease, undergoing total mastectomy
Number of subjects: 10873

Group type: EXPERIMENTAL
Intervention: Residing in a higher income area; having progesterone receptor-positive tumors; receipt of chemotherapy, radiotherapy, and endocrine therapy
Number of subjects: 10873
Study: 30945623

Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine (arm A; n=27)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 8 mg dexamethasone (reference arm C; n=27)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Functional Living Index‐Emesis (FLIE) questionnaire
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Patient's satisfaction with antiemetic coverage
Number of subjects: 81
Study: 28260692

Group type: EXPERIMENTAL
Intervention: Individualized glycemic goals
Number of subjects: 278
Study: 25185788

Group type: EXPERIMENTAL
Intervention: Dynamic humeral centering (DHC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonspecific mobilization
Number of subjects: 0
Study: 23286749

Group type: EXPERIMENTAL
Intervention: Severe head injury ≤ 1 year before diagnosis
Number of subjects: 4004

Group type: COMPARATOR
Intervention: Severe head injury > 3 years before diagnosis
Number of subjects: 4004

Group type: COMPARATOR
Intervention: Subtypes of head injury or repeated injuries > 3 years before diagnosis
Number of subjects: 4004
Study: 21631509

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (oral hygiene instructions and subgingival scaling and root planing)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 18832879

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Thymidine analogue-containing regimen (control)
Number of subjects: 1111
Study: 16476678

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (n = 24) for 15 days before FSH treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo gel (n = 25) for 15 days before FSH treatment
Number of subjects: 49
Study: 13129422

Group type: EXPERIMENTAL
Intervention: CABG and GER (Group II)
Number of subjects: 110

Group type: COMPARATOR
Intervention: CABG alone (Group I)
Number of subjects: 110
Study: 10947032

Group type: EXPERIMENTAL
Intervention: Auto-titrating, self-adjusting device (APAP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard nasal continuous positive airway pressure (CPAP)
Number of subjects: 60
Study: 9032214

Group type: EXPERIMENTAL
Intervention: Fatal asthma patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonfatal asthma patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 8321836

Group type: EXPERIMENTAL
Intervention: Felodipine extended-release (ER) tablets 10 mg under fasting conditions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Felodipine extended-release (ER) tablets 10 mg under nonfasting conditions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Felodipine extended-release (ER) tablets 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Felodipine extended-release (ER) tablets 10 mg with food
Number of subjects: 8
Study: 3963319

Group type: EXPERIMENTAL
Intervention: Oral flunitrazepam
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Oral pentobarbital
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Oral physiological NaCl solution
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Intramuscular droperidol/fentanyl
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Intramuscular physiological NaCl solution
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Oral premedication
Number of subjects: 600

Group type: COMPARATOR
Intervention: Parenteral premedication
Number of subjects: 600
Study: 29730741

Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT) with highly mineralized sulfate water
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tap water (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT)
Number of subjects: 100
Study: 27279970

Group type: EXPERIMENTAL
Intervention: Sombeza Water and Sanitation Improvement Program (SWASIP)
Number of subjects: 250
Study: 24401359

Group type: EXPERIMENTAL
Intervention: Subgroup A (etched and primed, composite resin applied)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Subgroup C (etched, primed, contaminated, composite resin applied)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Subgroup B (etched, contaminated with artificial saliva, primed, composite resin applied)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Subgroup D (etched, primed, contaminated, primer applied a second time, composite resin applied)
Number of subjects: 160
Study: 22519922

Group type: EXPERIMENTAL
Intervention: Bavisant 1 mg/day
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Bavisant 3 mg/day
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Bavisant 10 mg/day
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg/day
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: OROS Methylphenidate 54 mg/day
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 20511610

Group type: EXPERIMENTAL
Intervention: subcutaneous methotrexate (scMTX)
Number of subjects: 151

Group type: COMPARATOR
Intervention: ciclosporin added to oral methotrexate (MTX)
Number of subjects: 151
Study: 19004157

Group type: EXPERIMENTAL
Intervention: Goal Survey
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Goal Survey plus Contract
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Goal Survey plus Consult
Number of subjects: 375
Study: 16171716

Group type: EXPERIMENTAL
Intervention: Multiwire gamma camera (MWGC) with motion correction
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multiwire gamma camera (MWGC) without motion correction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Resting left ventricular (LV) ejection fraction (EF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Peak exercise EF by MWGC uncorrected
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Peak exercise EF by MWGC corrected
Number of subjects: 100
Study: 12889354

Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg/daily)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Combination of leflunomide and methotrexate
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Detralex in combination with methotrexate
Number of subjects: 189
Study: 10471542

Group type: EXPERIMENTAL
Intervention: Texx 300
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Jarsin 300
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 8707552

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Meperidine 50 mg plus promethazine 25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study: 1873003

Group type: EXPERIMENTAL
Intervention: 4 to 8 mg perindopril given once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: 25 to 50 mg captopril given twice daily
Number of subjects: 20
Study: 6375370

Group type: EXPERIMENTAL
Intervention: TMP/STX (cotrimoxazole)
Number of subjects: 63
Study: 29908708

Group type: EXPERIMENTAL
Intervention: HFpEF in patients ≥75 years
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Older age group
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Combination of clinical parameters (age, pulmonary rales, systolic blood pressure, cause of heart failure, osteoporosis, current smoking, NT‐proBNP, haemoglobin, QRS width, heart rhythm)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Symptom history and clinical examination alone
Number of subjects: 622
Study: 26847139

Group type: EXPERIMENTAL
Intervention: Urodynamic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine practice without urodynamic testing
Number of subjects: 0
Study: 25247335

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day for 12 weeks)
Number of subjects: 281
Study: 22614228

Group type: EXPERIMENTAL
Intervention: Quercetin (1,000 mg·d⁻¹ for 8.5 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20233179

Group type: EXPERIMENTAL
Intervention: Oral clotrimazole troches 10 mg taken three times daily for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral midazolam 2 mg or intravenous midazolam 0.025 mg kg(‐1) without clotrimazole
Number of subjects: 10
Study: 18554207

Group type: EXPERIMENTAL
Intervention: Voltage mapping-guided endomyocardial biopsy (EMB)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Voltage mapping
Number of subjects: 22
Study: 17968997

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no physiotherapy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Physiotherapy and Control
Number of subjects: 18
Study: 14992842

Group type: EXPERIMENTAL
Intervention: Ergonomics training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pre- and posttests without training (Control)
Number of subjects: 50
Study: 10594437

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask using a fibreoptic bronchoscope (group L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Macintosh laryngoscope and gum elastic bougie (group C)
Number of subjects: 40
Study: 9355948

Group type: EXPERIMENTAL
Intervention: semirigid mini-endoscope and Swiss Lithoclast
Number of subjects: 147

Group type: COMPARATOR
Intervention: conventional rigid ureteroscope and ultrasound
Number of subjects: 147
Study: 8210718

Group type: EXPERIMENTAL
Intervention: ketotifen 1 mg b.i.d.
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 3534848

Group type: EXPERIMENTAL
Intervention: Capozide (50 mg captopril and 25 mg hydrochlorothiazide)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Moduretic (50 mg hydrochlorothiazide and 5 mg amiloride)
Number of subjects: 63
Study: 31267293

Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 1327

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1327
Study: 28039477

Group type: EXPERIMENTAL
Intervention: New risk assessment model for PSA 4-10 ng/mL
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: New risk assessment model for PSA 10-50 ng/mL
Number of subjects: 702

Group type: COMPARATOR
Intervention: PSA alone for PSA 4-10 ng/mL
Number of subjects: 702

Group type: COMPARATOR
Intervention: PSA alone for PSA 10-50 ng/mL
Number of subjects: 702
Study: 25727914

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL) 20g per day for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoenergetic/isomacronutrient placebo (PLA)
Number of subjects: 20
Study: 23786793

Group type: COMPARATOR
Intervention: Alzheimer's disease (AD) patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Mild cognitive impairment (MCI) patients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Normal controls (NC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Comparison of perceptual and response interference effects
Number of subjects: 38
Study: 20299114

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3528

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor use
Number of subjects: 3528

Group type: COMPARATOR
Intervention: Nonuse of glycoprotein IIb/IIIa inhibitor
Number of subjects: 3528
Study: 18992183

Group type: EXPERIMENTAL
Intervention: Natural frequencies
Number of subjects: 285

Group type: COMPARATOR
Intervention: Percentages
Number of subjects: 285

Group type: COMPARATOR
Intervention: Verbal descriptors
Number of subjects: 285
Study: 16866127

Group type: EXPERIMENTAL
Intervention: Evidence-based approach in Orthodontics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study: 12938639

Group type: EXPERIMENTAL
Intervention: Rebif 22 micrograms three times a week for 1 year
Number of subjects: 167
Study: 10951448

Group type: EXPERIMENTAL
Intervention: STIR MRI
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quantitative assessments of signal intensity ratio (SIR) from STIR MRI
Number of subjects: 90

Group type: COMPARATOR
Intervention: EMG
Number of subjects: 90
Study: 9165806

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Comparison between TT and PMR
Number of subjects: 82
Study: 8464977

Group type: EXPERIMENTAL
Intervention: Back injury prevention program including education, training, physical fitness activities, and ergonomic improvement.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis of the back injury prevention program.
Number of subjects: 205
Study: 2939239

Group type: EXPERIMENTAL
Intervention: Latamoxef (1 g intravenous injection at induction of anaesthesia)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Tetracycline (peritoneal and wound lavage)
Number of subjects: 431
Study: 31733781

Group type: EXPERIMENTAL
Intervention: Multimodal approach including patient education, manual therapy, therapeutic exercise programs, and orthotic provision
Number of subjects: 0
Study: 30106369

Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM+)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No Remote Monitoring (RM-)
Number of subjects: 12
Study: 27352489

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zhongliao (BL 33) and Huiyang (BL 35)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham acupuncture and placebo EA
Number of subjects: 42
Study: 25226004

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 24
Study: 22776534

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT, 16 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine (30-60 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of CBT and antidepressant medication (for non-remitters)
Number of subjects: 0
Study: 20116697

Group type: EXPERIMENTAL
Intervention: Resorbable plate
Number of subjects: 272

Group type: COMPARATOR
Intervention: Nonresorbable plate
Number of subjects: 272
Study: 17621017

Group type: COMPARATOR
Intervention: Radiosurgery (RS)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Microsurgery (MS)
Number of subjects: 39
Study: 15054512

Group type: EXPERIMENTAL
Intervention: Cariporide 20 mg
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Cariporide 80 mg
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Cariporide 120 mg
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 11850979

Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone stimulation test
Number of subjects: 40
Study: 9758074

Group type: EXPERIMENTAL
Intervention: Vibration pain provocation
Number of subjects: 78

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combined evaluation of vibration pain provocation and MRI
Number of subjects: 78
Study: 7949544

Group type: EXPERIMENTAL
Intervention: Spontaneous proliferation (SP) of peripheral blood mononuclear cells (PBMC) in patients with mild episodes of clinical acute rejection (n=2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Spontaneous proliferation (SP) of PBMC in liver transplant patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Spontaneous proliferation (SP) of PBMC in patients with systemic infections
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Spontaneous proliferation (SP) of PBMC in patients with elevated TAC‐A score (n=8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SP of PBMC in patients treated with anti‐interleukin‐2‐receptor antibody, BT563 (n=8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Correlation between SP of PBMC and TAC‐A score
Number of subjects: 22
Study: 2884410

Group type: EXPERIMENTAL
Intervention: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) at doses of 10 to 800 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) at 800 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) with a fourth dose
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-immunised controls
Number of subjects: 15
Study: 29098900

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% topical spray
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% topical spray
Number of subjects: 53

Group type: COMPARATOR
Intervention: Vehicle topical spray
Number of subjects: 53
Study: 27026570

Group type: EXPERIMENTAL
Intervention: HIIE in dry land
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: HIIE in immersed condition
Number of subjects: 42

Group type: COMPARATOR
Intervention: MICE
Number of subjects: 42
Study: 22633317

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study: 22889095

Group type: EXPERIMENTAL
Intervention: AgNano 10 mg/kg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: AgNano 20 mg/kg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (0 mg/kg AgNano)
Number of subjects: 144
Study: 20214066

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding at Zusanli (ST 36), Pishu (BL 20), Weishu (BL 21)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Lysine Dicalcium Phosphate particles (Control)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Flour capsule (Placebo)
Number of subjects: 300